In a notable development, shares of Harrow, Inc. (NASDAQ: HROW) experienced a significant rise in market value following the relaunch of its product, TRIESENCE. As of the most recent market assessment, HROW stock surged by 6.67%, trading at $48.94. This increase reflects strong investor enthusiasm surrounding the company’s strategic move.
Harrow relaunched TRIESENCE Bringing Critical Relief to Ophthalmology
Triamcinolone acetonide injectable suspension (TRIESENCE) 40 mg/mL has been reintroduced by Harrow, which is a major step towards filling a key need in the ophthalmology industry. TRIESENCE is a synthetic corticosteroid without preservative that has been approved by the FDA. It is intended to be used during vitrectomy operations and to treat ocular inflammatory disorders that do not improve with topical corticosteroids.
Millions of patients have benefitted from Harrow’s reliable FDA-approved solution for ophthalmologists, which was reintroduced into the U.S. market. This relaunch followed extensive efforts to rebuild the product’s supply chain, involving global collaboration between Harrow and technical experts from across the world.
A Collaborative Effort
The successful relaunch required Harrow to completely rebuild the TRIESENCE supply chain, involving extensive collaboration with technical experts from global partners. The availability of an FDA-approved, preservative-free corticosteroid is paramount for both office-based and surgical procedures.
TRIESENCE is distinguished by its pharmaceutically elegant injectable suspension, which provides enhanced visibility against the retina during vitrectomy, thus facilitating improved surgical outcomes.
Addressing Previous Shortages
The reintroduction of TRIESENCE comes after it spent over five years on the FDA Drug Shortage List, with two years of depleted inventory. This gap in availability forced many eyecare professionals to resort to less optimal off-label alternatives, such as modifying preserved Kenalog-40, which carried potential risks.
With TRIESENCE back on the market, Harrow is poised to deliver safer and more effective treatment options, thereby enhancing patient care and clinical outcomes. The product’s potent anti-inflammatory properties are crucial in managing severe ocular inflammatory conditions that resist topical therapies, effectively reducing swelling, pain, and the risk of long-term complications.
